Rich is a Managing Partner at venBio with experience as a physician, entrepreneur, and life science investor. He currently serves on the board of Ventyx Biosciences, Acelyrin, Attralus, Aeovian Pharmaceuticals, NorthSea Therapeutics, and Arrakis Therapeutics and served as a board member or observer of Pharvaris, Akero Therapeutics and Harmony Biosciences.

Prior to joining venBio, Rich served as the head of translational medicine at Pliant Therapeutics. As a key member of the initial management team, Rich participated in the formation and launch of Pliant Therapeutics from Third Rock Ventures. During his tenure at Third Rock Ventures, Rich was responsible for company creation to transform new areas of science into innovative drug discovery companies.

He began his career as a resident physician in Harvard’s Plastic and Reconstructive Surgery Program. Rich has published numerous articles in top-tier peer-reviewed journals including Nature Medicine and Nature Nanotechnology, holds more than a dozen patents, and was named one of Forbes “30 Under 30” in Science and Healthcare. Rich holds a BSE in Bioengineering from the University of Pennsylvania where he graduated summa cum laude. He received his M.D. and Ph.D. in Bioengineering from Stanford University in the Medical Scientist Training Program.